HLB Therapeutics Co.,Ltd.
115450
Rang in aandelen
#18248
HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the... HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the creation of pharmaceutical products for both the South Korean and international markets. A significant part of its research and development initiatives includes GBT-201, a compound utilizing Thymosin beta designed to treat various eye ailments such as dry eye syndrome and neurotrophic keratopathy. Additionally, the company is advancing OKN-007 as a potential therapy for glioblastoma brain tumors. Beyond its pharmaceutical endeavors, HLB Therapeutics is also involved in the wholesale distribution of vaccines and the production of electrical and electronic components like motors, pumps, and transformers. The company, which established its roots in 2000 and is based in Seongnam, South Korea, underwent a name change in December 2021, transitioning from its former identity as G-treeBNT Co., Ltd. to its current designation.
Aandeelprijs
$2.02
Marktkapitalisatie
$190.66M
Verandering (1 dag)
7.96%
Verandering (1 jaar)
-1.16%
Land
KR
Handel HLB Therapeutics Co.,Ltd. (115450)
Categorie
Healthcare
Koersgeschiedenis voor HLB Therapeutics Co.,Ltd. (115450)
Hoogste slotkoers: $1.94 op 2026-10-01
Laagste slotkoers: $9.82 op 2010-03-01
Laagste slotkoers: $9.82 op 2010-03-01
Koersgeschiedenis van HLB Therapeutics Co.,Ltd. van 2010 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | -4.53% |
| 2025 | -69.48% |
| 2024 | 142.67% |
| 2023 | -24.36% |
| 2022 | -34.28% |
| 2021 | -50.71% |
| 2020 | 1.61% |
| 2019 | 7.70% |
| 2018 | -17.13% |
| 2017 | 106.04% |
| 2016 | 24.88% |
| 2015 | 254.54% |
| 2014 | 20.37% |
| 2013 | -14.85% |
| 2012 | -28.46% |
| 2011 | -62.15% |
| 2010 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
